Form 4: Prothena Corp Director Dennis J. Selkoe Acquires 15,000 Stock Options

Director Dennis J. Selkoe of Prothena Corp acquired 15,000 stock options at an exercise price of $22.39 on May 15, 2024.

Summary

• On May 15, 2024, Dennis J. Selkoe, a director of Prothena Corp Public Ltd Co, acquired 15,000 stock options.
• The exercise price for these options is $22.39.
• The options vest on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025, assuming continuous service as a director.
• The options expire on May 15, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is neither particularly positive nor negative. It reflects standard corporate governance practices.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continuous service as a director, suggesting an expectation of continued involvement and commitment from Dennis J. Selkoe.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of directors with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule, contingent on continued service, is a standard practice to incentivize long-term commitment.
• Comparing the exercise price and the number of options granted to similar companies and director roles would provide a benchmark for assessing the competitiveness of this compensation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates